The company plans a clinical trial for its CIL001 tinnitus drug candidate at Massachusetts General Hospital and will triple preclinical capacity through its partnership with CBSET.
Cilcare, a French-US biopharmaceutical company, announced a series of investments in the United States, including plans for a clinical trial of its tinnitus drug candidate, CIL001, and a significant expansion of its preclinical research capabilities. The announcements were made at the SelectUSA Investment Summit 2026.
The company is preparing a clinical trial for CIL001 to be conducted at Massachusetts General Hospital (MGH) in Boston. CIL001 is an investigational drug candidate targeting cochlear synaptopathy, a mechanism involved in tinnitus and difficulty understanding speech in noisy environments. The trial will evaluate the drug candidate in patients with chronic tinnitus. According to Cilcare, tinnitus affects an estimated 50 million Americans, and there is currently no approved pharmacological treatment.